Ambrx Biopharma Inc. (AMAM) Financials

AMAM Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 271.5 million 29.1 million
2023-06-30 279.9 million 29.6 million
2023-03-31 210.6 million 28.0 million
2022-12-31 147.0 million 29.1 million

AMAM Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -19.2 million 4.8 million
2023-06-30 -13.9 million 2.9 million
2023-03-31 -13.0 million 1.9 million
2022-12-31 -12.8 million 1.2 million

AMAM Net Income

No data available :(

AMAM Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 225.3 million - 10.5 million
2023-06-30 235.1 million - 11.0 million
2023-03-31 157.5 million - 11.5 million
2022-12-31 84.5 million - 12.0 million

AMAM Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 62.3 million
2023-06-30 55.9 million
2023-03-31 45.0 million
2022-12-31 38.6 million

AMAM Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 298000 16.3 million 9.4 million -
2023-06-30 783000 14.4 million 5.9 million -
2023-03-31 783000 9.8 million 6.1 million 1.3 million
2022-12-31 47000 10.3 million 5.6 million 681500

AMAM Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 53000 -
2023-06-30 1.1 million -
2023-03-31 24000 -
2022-12-31 2.2 million -

AMAM

Price: $28

52 week price:
4.45
28.15

Earnings Per Share: 0.42 USD

P/E Ratio: 66.14

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 261163

Market Capitalization: 1.8 billion

Links: